August 17, 2026 08:40 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
After SC rebuke, BCI chief apologises to NALSAR students over enrolment freeze row | Independence Day: PM Modi’s big youth pitch— AI training, free coaching amid exam row and job concerns | ‘Shakti Ki Saptadhara’: Modi reveals 7 pillars to power India’s next leap in his I-Day speech from Red Fort | West Bengal STF arrests 3 more suspected Pakistani spies in Cooch Behar | Bengal man arrested in Bengaluru over terror links, Afghanistan travel plan | Ajit Doval breaks silence on Operation Sindoor in Discovery’s explosive new docuseries | Rahul Gandhi's 'mock hug' taunt sparks row; Centre stresses 'mutual respect' with Italy | Delhi on high alert: Bomb threat to High Court, airport and multiple locations ahead of I-Day | ‘Who are they to interfere?’: CJI Surya Kant slams Bar Council of India over NALSAR students’ enrolment row | 'Shows how low Congress has sunk': BJP slams Rahul Gandhi over Modi foreign policy jibe
Serum Institute of India

Serum Institute seeks financial assistance from govt to boost capacity

| @indiablooms | Apr 08, 2021, at 04:00 am

New Delhi/IBNS: Adar Poonawalla, the CEO of world's largest vaccine manufacturer Serum Institute of India (SII), has told NDTV it needs Rs 3,000 crore in assistance from the Indian government to expand its production capacity which is currently "very stretched" in wake of the export restrictions imposed by the government last month.

Poonawalla stated that the Indian government pays it far less per shot of the vaccine than what is earned in exports, necessitating funding to boost the production capacity.

"This was never budgeted or planned initially, because we were supposed to export and get the funding from export countries but now that that is not happening, we have to find other innovative ways to build our capacity," Poonawalla said.

He admitted that SII is not able to supply the vaccine to every Indian who needs it and at the moment it is prioritising India's needs.

He said the Indian government is paying Rs 150 per shot which is profitable but not enough for reinvesting.

"The price that is set is profitable, however it is not profitable enough to re-invest substantially in building capacity," Poonawalla said.

SII has appealed to the government for financial help after restrictions were imposed on the exports of Covishield to battle a steep rise in cases at home.

Poorer countries as well as some rich nations relied heavily on the Serum Institute of India (SII) to vaccinate their citizens with the AstraZeneca vaccine.

Serum Institute produces over two million doses of Covishield per day at its current capacity.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.